Drug Trial Radar · NCT07673744
A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following Induction With Efgartigimod Administration in Participants With Myasthenia Gravis (MG)
Last checked: Nov 20, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
120
Planned (sponsor's estimate)
Start
Nov 1, 2026
Primary completion
Jul 1, 2028
Study completion Jan 1, 2030
Sponsor
- Lead sponsor
- TG Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 29, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of this study is to evaluate the efficacy of ublituximab in adult participants with MG responding to treatment with efgartigimod.
Conditions
- Myasthenia Gravis
Interventions
UblituximabDrug
Administered as an IV infusion.
PlaceboDrug
Administered as an IV infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to Onset of a Clinical Worsening EventTime frame: Up to Week 24
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
TG Therapeutics Investigational Trial Site
Colorado Springs, Colorado · Recruiting
TG Therapeutics Investigational Trial Site
Colorado Springs, Colorado · Recruiting
TG Therapeutics Investigational Trial Site
Clearwater, Florida · Recruiting
TG Therapeutics Investigational Trial Site
Maitland, Florida · Recruiting
TG Therapeutics Investigational Trial Site
Farmington Hills, Michigan · Recruiting
TG Therapeutics Investigational Trial Site
New Bern, North Carolina · Recruiting
TG Therapeutics Investigational Trial Site
Greenville, South Carolina · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.